Abbott/Sandoz’ Hytrin Agreement Violates Antitrust Law, Judge Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A provision under which Sandoz (formerly Geneva) agreed not to market generic terazosin until an appellate ruling in underlying patent litigation “exceeded the scope” of the potential exclusionary effect of Abbott’s patent, court says. The ruling marks the second time the judge has found the agreement to violate antitrust law.